The 400-Member Protein Family That Neuroscience Has Almost Entirely Ignored

Pull up the target list from any major neuroscience pipeline review and you will see the same architecture repeated: GPCR agonists, ion channel modulators, monoamine reuptake inhibitors. The field has spent four decades recycling the same molecular machinery while a protein superfamily of more than 400 members sits largely untouched. A comprehensive review in Nature Reviews Drug Discovery published in 2026 now makes the case that solute carrier (SLC) membrane transporters represent one of the most consequential untapped target classes in CNS medicine. The numbers demand attention: SLC transporters constitute an estimated 3% of human protein targets of approved drugs, and only two SLCs rank in the top 20 drug targets by sales and NIH funding. Out of a superfamily exceeding 400 members, roughly a third have no known ligand at all. For a trial designer building a neuro or psychiatry protocol right now, that statistic carries a specific operational weight. Targeting a largely uncharted protein family means entering a regulatory environment that has not fully developed the evidentiary standards to evaluate your molecule. The FDA's existing guidance on transporter-mediated drug-drug interactions focuses primarily on pharmacokinetic gatekeeping: will your compound inhibit transporters that affect the exposure of co-administered drugs? That framing, captured in the Agency's guidance on drug interaction studies, was designed to protect patients from unexpected toxicity, not to establish proof-of-concept for transporter-mediated pharmacodynamics in the CNS. Those are fundamentally different questions, and the field is starting to realize they require fundamentally different trial architectures. Why the Biology Keeps Getting Misread SLC transporters control the movement of neurotransmitters, amino acids, metal ions, glucose, and neuroactive steroids across cellular membranes. Several are dysregulated in Parkinson's disease, major depressive disorder, ALS, and schizophrenia. The core mechanistic problem for drug developers is one of isoform complexity layered on top of tissue specificity layered on top of directional transport ambiguity. A compound that inhibits SLC6A4, the serotonin transporter, will look like a selective serotonin reuptake inhibitor at the synapse. But move ten members down the family and you are in territory where the same inhibitory mechanism might impair cellular nutrient uptake rather than tune neurotransmitter clearance. This is the single principle that trial designers working in this space must internalize before they write the first line of a protocol: the pharmacological effect of SLC modulation is not predictable from the inhibition/activation binary that governs most small-molecule CNS targets. Direction of transport, subcellular localization, co-transporter dependencies, and substrate competition all determine what happens when you hit a specific SLC in a specific brain region. Preclinical packages that do not characterize these variables with tissue-specific precision will generate clinical candidates whose mechanism is incompletely understood at the point of IND submission. That incompleteness has consequences in the clinic. The fedratinib story is instructive precisely because the SLC mechanism was not the intended pharmacology. During the JAKARTA and JAKARTA-2 trials, the FDA placed a clinical hold on fedratinib in 2013 after cases of Wernicke's encephalopathy emerged, a thiamine-deficiency syndrome later attributed partly to the drug's inhibition of a thiamine transporter. The drug was targeting JAK2; the transporter was an off-target casualty. When the SLC mechanism is the intended pharmacology rather than a confound, sponsors will need to demonstrate both engagement of the target transporter and the functional downstream consequence in the CNS, a two-step evidentiary burden that current guidance documents do not specify. The Regulatory Blind Spot Here is the counterintuitive reality that most coverage of this review will miss. The widespread assumption is that SLC transporters are underexploited because the biology is too hard. The more operationally accurate explanation is that the regulatory pathway for demonstrating CNS transporter pharmacodynamics in humans remains undefined, which suppresses investment, which suppresses the IND volume, which ensures the pathway stays undefined. It is a closed loop that the biology alone cannot break open. The FDA's transporter guidance framework, built around in vitro inhibition constants and clinical DDI studies, tells sponsors how to characterize a transporter as a safety variable. It does not tell them how to design a proof-of-concept trial where the transporter is the efficacy variable. Existing guidance documents do not specify what a valid pharmacodynamic biomarker for SLC engagement looks like in a CNS indication, and the field lacks established precedent for what the Agency expects as evidence that a novel SLC modulator reaches its target in the brain at therapeutically relevant concentrations. Positron emission tomography occupancy studies have established that standard for most receptor classes; the SLC field has not yet developed an equivalent consensus methodology. Consider what that means at the Phase I/II design stage. A sponsor developing an SLC7A11 inhibitor for glutamate dysregulation in treatment-resistant schizophrenia would need to justify both the PK/PD model and the biomarker strategy from first principles, without an FDA-recognized framework to anchor the Type B meeting discussion. The reviewer on the other side of that meeting has no precedent file to consult. That asymmetry does not kill programs, but it adds significant time to iterative guidance-seeking in every early-phase program in this space, a cost that smaller biotechs with SLC assets in their pipelines are absorbing right now. The Nature Reviews Drug Discovery analysis notes that numerous SLC transporters show dysregulated expression specifically in CNS tissue compared to peripheral tissues, a selectivity profile that is pharmacologically attractive precisely because it reduces the theoretical risk of systemic off-target effects. But clinical trial designers know that tissue selectivity in expression data does not automatically translate to CNS selectivity in drug distribution. The blood-brain barrier transport characteristics of SLC-targeted compounds add another layer of mechanistic work that must be completed before Phase II enrollment makes scientific sense. Sponsors who skip that work to accelerate timelines will find themselves facing a complete response letter built on mechanistic ambiguity rather than efficacy failure. What Protocol Designers Must Build In Now The practical implication of all this is not that the SLC field is unviable. The therapeutic rationale is compelling enough to attract serious drug hunters: control over nutrient delivery, neurotransmitter gradients, and ionic homeostasis at the cellular level gives SLC-targeted drugs a precision that upstream signaling targets cannot match. The implication is that trial designers need to front-load the mechanistic work that the regulatory framework does not yet require but that reviewers will demand when submissions arrive. That means three things in protocol architecture. First, CNS-targeted SLC programs need centrally assessed pharmacodynamic endpoints tied to the specific transport mechanism, not surrogate clinical endpoints borrowed from approved drug classes with different mechanisms. A protocol relying on Hamilton Depression Rating Scale improvement as the primary evidence of SLC target engagement is building on borrowed credibility. Second, the drug-drug interaction characterization required under existing FDA guidance must be extended to cover the SLC isoforms most relevant to CNS co-medications, because neuropsychiatry patients rarely take one drug, and the interaction landscape for novel SLC modulators is by definition uncharacterized. Third, biomarker strategies need to be locked before Phase I, not retrofitted at Phase II, because the window to establish transporter engagement in early human studies is narrow and may not be recoverable once the dose-ranging work is complete. The review in Nature Reviews Drug Discovery frames SLC transporters as an emerging opportunity. From a trial operations perspective, the more precise framing is that they represent an emerging obligation: the field now has the genetic evidence, the expression data, and the pharmacological tools to build SLC-targeted CNS programs, which means the next cycle of neuroscience failures will belong to sponsors who had the target right and the trial design wrong. The FDA's guidance infrastructure will catch up eventually. It always does, one complete response letter at a time. References